Legal & General Group
ALDX icon

Legal & General Group’s Aldeyra Therapeutics ALDX Stock Holding History

Legal & General Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,940
Closed -$8.35K – 3397
2026
Q1 		$8.35K Sell
4,940
-705
-12% -$3.09K ﹤0.01% 3227
2025
Q4 		$29.2K Sell
5,645
-191
-3% -$981 ﹤0.01% 2884
2025
Q3 		$30.5K Hold
5,836
– – ﹤0.01% 2886
2025
Q2 		$22.4K Buy
5,836
+1,439
+33% +$3.72K ﹤0.01% 2962
2025
Q1 		$25.3K Hold
4,397
– – ﹤0.01% 2863
2024
Q4 		$21.9K Hold
4,397
– – ﹤0.01% 2986
2024
Q3 		$23.7K Buy
4,397
+280
+7% +$1.33K ﹤0.01% 2984
2024
Q2 		$13.6K Sell
4,117
-1,010
-20% -$3.96K ﹤0.01% 3193
2024
Q1 		$16.7K Sell
5,127
-4,213
-45% -$13.9K ﹤0.01% 3037
2023
Q4 		$32.8K Sell
9,340
-28,254
-75% -$87.2K ﹤0.01% 2880
2023
Q3 		$251K Sell
37,594
-303
-0.8% -$2.25K ﹤0.01% 2669
2023
Q2 		$318K Buy
+37,897
New +$373K ﹤0.01% 2614
2022
Q2 		– Sell
-5,289
Closed -$24K – 3518
2022
Q1 		$24K Buy
5,289
+307
+6% +$1.22K ﹤0.01% 3182
2021
Q4 		$20K Sell
4,982
-150
-3% -$1.14K ﹤0.01% 3275
2021
Q3 		$45K Hold
5,132
– – ﹤0.01% 3002
2021
Q2 		$58K Buy
+5,132
New +$61.7K ﹤0.01% 2903
2020
Q2 		– Sell
-3,904
Closed -$10K – 3410
2020
Q1 		$10K Hold
3,904
– – ﹤0.01% 3148
2019
Q4 		$23K Buy
3,904
+622
+19% +$3.59K ﹤0.01% 3140
2019
Q3 		$17K Hold
3,282
– – ﹤0.01% 3180
2019
Q2 		$20K Hold
3,282
– – ﹤0.01% 3189
2019
Q1 		$30K Hold
3,282
– – ﹤0.01% 2925
2018
Q4 		$27K Buy
3,282
+922
+39% +$9.45K ﹤0.01% 2948
2018
Q3 		$33K Hold
2,360
– – ﹤0.01% 2976
2018
Q2 		$19K Buy
+2,360
New +$18.8K ﹤0.01% 3198

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Legal & General Group's ALDX Position: Q2 2026 in Review

Legal & General Group sold out of Aldeyra Therapeutics (ALDX) in Q2 2026, closing a stake of 4,940 shares — an estimated $8.35K sold.

Legal & General Group first reported a position in ALDX in Q2 2018 and held it in 24 quarters. The position peaked at $318K in Q2 2023. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Legal & General Group reported no remaining Aldeyra Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Legal & General Group sold 4,940 Aldeyra Therapeutics shares in Q2 2026, an estimated $8.35K.
  • Legal & General Group first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 24 quarters.
  • Legal & General Group's Aldeyra Therapeutics position peaked at $318K in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.